Adaptimmune Therapeutics Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/28/2025)
| Balance Sheet | Total Assets | 245,963,000.00 | ROE | – |
| Balance Sheet | Total Equity | 11,849,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -2,720,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -75,926,000.00 | – | – |
| Cashflow | Operating Cash Flow | -73,206,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.05 | Div. Yield | – |
| Income | Net Income | -70,814,000.00 | P/E | – |
| Income | Shares Outstanding | 1,535,650,000.00 | P/B | – |
| Income | Total Revenue | 178,032,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.adaptimmune.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more